Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities: 2021-2024

Historic Cash from Financing Activities for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $348,000.

  • Amylyx Pharmaceuticals' Cash from Financing Activities rose 239407.50% to $191.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $257.3 million, marking a year-over-year increase of 54888.68%. This contributed to the annual value of $348,000 for FY2024, which is 90.18% down from last year.
  • Amylyx Pharmaceuticals' Cash from Financing Activities amounted to $348,000 in FY2024, which was down 90.18% from $3.5 million recorded in FY2023.
  • Amylyx Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $431.8 million during FY2022, with a 5-year trough of $348,000 in FY2024.
  • Its 3-year average for Cash from Financing Activities is $145.2 million, with a median of $3.5 million in 2023.
  • In the last 5 years, Amylyx Pharmaceuticals' Cash from Financing Activities spiked by 172.41% in 2022 and then tumbled by 99.18% in 2023.
  • Over the past 4 years, Amylyx Pharmaceuticals' Cash from Financing Activities (Yearly) stood at $158.5 million in 2021, then soared by 172.41% to $431.8 million in 2022, then plummeted by 99.18% to $3.5 million in 2023, then crashed by 90.18% to $348,000 in 2024.